WEIS MARKETS REPORTS THIRD QUARTER 2026 RESULTS

WEIS MARKETS INC (WMK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ NEWS RELEASE ​ FOR IMMEDIATE RELEASE Contact: Dennis Curtin Weis Markets, Inc. 570-847-3636 dennis.curtin@weismarkets.com ​ ​ WEIS MARKETS REPORTS THIRD QUARTER 2026 RESULTS Third Quarter 2026 total revenue increased 3.0% and comparable store sales increased 1.3%

Original reporting
Published Nov 3, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$WMK
Bullish
high confidence
Mentioned
$WMK
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$WMKBullishMed
01

Why it matters

Earnings beat and dividend raise provide fresh data for valuation models.

02

Market read

First‑report earnings with modest revenue growth and dividend increase, relevant for retail investors.

03

What to watch

Pharmacy pricing headwinds from the Inflation Reduction Act could suppress growth.

Relevance 7/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readWMK · Third Quarter 2026 · ended September 26, 2026

WEIS MARKETS REPORTS THIRD QUARTER 2026 RESULTS

✓Solid quarter

Third-quarter total revenue increased 3.0%, gross profit increased 5.8%, income from operations increased 38.6%, and net income increased 31.4%, while comparable store sales excluding fuel decreased 1.2%.

Revenue
$1.27B
EPS · GAAP
$ 0.90

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
13 Weeks Ended September 26, 2026 - Net salesGAAP$1.27B––
13 Weeks Ended September 26, 2026 - Other revenueGAAP$4.27M––
13 Weeks Ended September 26, 2026 - Total revenueGAAP$1.28B–3.0%
13 Weeks Ended September 26, 2026 - Cost of sales, including advertising, warehousing and distribution expensesGAAP$954.5M––
13 Weeks Ended September 26, 2026 - Gross profit on salesGAAP$324.6M–5.8%
13 Weeks Ended September 26, 2026 - Gross profit marginGAAP25.5%––
13 Weeks Ended September 26, 2026 - Operating, general and administrative expensesGAAP$296.1M––
13 Weeks Ended September 26, 2026 - Income from operationsGAAP$28.50M–38.6%
13 Weeks Ended September 26, 2026 - Investment income (loss) and interest expenseGAAP$2.09M––
13 Weeks Ended September 26, 2026 - Other income (expense)GAAP$ (460)––
13 Weeks Ended September 26, 2026 - Income before provision for income taxesGAAP$30.13M––
13 Weeks Ended September 26, 2026 - Provision for income taxesGAAP$7.92M––
13 Weeks Ended September 26, 2026 - Net incomeGAAP$22.21M–31.4%
13 Weeks Ended September 26, 2026 - Weighted-average shares outstanding, basic and dilutedGAAP24,744,597––
13 Weeks Ended September 26, 2026 - Cash dividends per shareGAAP$ 0.34––
13 Weeks Ended September 26, 2026 - Basic and diluted earnings per shareGAAP$ 0.90––
13 Weeks Ended September 26, 2026 - Comparable store sales (individual year)GAAP1.3 %–1.3 %
13 Weeks Ended September 26, 2026 - Comparable store sales (two-year stacked)non-GAAP3.8––
13 Weeks Ended September 26, 2026 - Comparable store sales, excluding fuel (individual year)GAAP(1.2)–(1.2)
13 Weeks Ended September 26, 2026 - Comparable store sales, excluding fuel (two-year stacked)non-GAAP1.3 %––
39 Weeks Ended September 26, 2026 - Net salesGAAP$3.80B––
39 Weeks Ended September 26, 2026 - Other revenueGAAP$12.91M––
39 Weeks Ended September 26, 2026 - Total revenueGAAP$3.81B–4.1%
39 Weeks Ended September 26, 2026 - Cost of sales, including advertising, warehousing and distribution expensesGAAP$2.83B––
39 Weeks Ended September 26, 2026 - Gross profit on salesGAAP$983.3M–7.8%
39 Weeks Ended September 26, 2026 - Gross profit marginGAAP25.9%––
39 Weeks Ended September 26, 2026 - Operating, general and administrative expensesGAAP$889.9M––
39 Weeks Ended September 26, 2026 - Income from operationsGAAP$93.31M–28.6%
39 Weeks Ended September 26, 2026 - Investment income (loss) and interest expenseGAAP$7.38M––
39 Weeks Ended September 26, 2026 - Other income (expense)GAAP−$2.53M––
39 Weeks Ended September 26, 2026 - Income before provision for income taxesGAAP$98.17M––
39 Weeks Ended September 26, 2026 - Provision for income taxesGAAP$25.25M––
39 Weeks Ended September 26, 2026 - Net incomeGAAP$72.92M–18.1%
39 Weeks Ended September 26, 2026 - Weighted-average shares outstanding, basic and dilutedGAAP24,744,597––
39 Weeks Ended September 26, 2026 - Cash dividends per shareGAAP$ 1.02––
39 Weeks Ended September 26, 2026 - Basic and diluted earnings per shareGAAP$ 2.95––
39 Weeks Ended September 26, 2026 - Comparable store sales (individual year)GAAP1.9 %–1.9 %
39 Weeks Ended September 26, 2026 - Comparable store sales (two-year stacked)non-GAAP3.6––
39 Weeks Ended September 26, 2026 - Comparable store sales, excluding fuel (individual year)GAAP(0.1)–(0.1)
39 Weeks Ended September 26, 2026 - Comparable store sales, excluding fuel (two-year stacked)non-GAAP1.8 %––

Capital returns

  • On October 29, 2026, the Board of Directors declared a quarterly cash dividend of $0.34 per share, payable on November 23, 2026, to shareholders of record as of November 9, 2026.

What drove it

  • Higher fuel sales, reflecting both retail price inflation and increased gallons sold, supported total revenue growth.
  • Sales from new stores supported revenue growth.
  • Improved store inventory shrink performance and lower costs within the internal supply chain helped drive higher gross profit margin.
  • The Company cited people, process and technology investments across stores, supply chain, manufacturing and the Store Support Center.
  • Third-quarter pharmacy sales were negatively impacted by approximately $14.56 million from Inflation Reduction Act Medicare maximum fair price provisions, reducing total revenue growth by approximately 1.2 percentage points.
  • Year-to-date pharmacy sales were negatively impacted by approximately $32.75 million from Inflation Reduction Act Medicare maximum fair price provisions, reducing total revenue growth by approximately 0.9 percentage points.

Concerns

  • Customers remained cautious with their spending and continued to seek affordability and value.
  • Comparable store sales excluding fuel decreased 1.2% in the third quarter and decreased 0.1% year to date.
  • Lower overall sales in pharmacy, dairy and produce partially offset third-quarter revenue growth.
  • Dairy sales reflected lower egg pricing compared with the prior year.
  • Produce sales were negatively affected by lower customer demand during the Cyclospora outbreak in the third quarter.
  • Lower investment income and a higher effective income tax rate moderated net-income growth.

What to watch

  • Comparable store sales excluding fuel following the third-quarter decrease of 1.2%.
  • The continuing effect of Inflation Reduction Act Medicare maximum fair price provisions on pharmacy sales.
  • Fuel sales, including retail price inflation and gallons sold.
  • The persistence of gross-profit benefits from store inventory shrink performance and internal supply-chain costs.
  • Dairy egg pricing and produce demand following the Cyclospora outbreak.

Analysis

Weis Markets reported a stronger 13-week third quarter ended September 26, 2026. Total revenue was $1.28 billion, up 3.0%, while gross profit increased 5.8% to $324.61 million and income from operations increased 38.6% to $28.51 million. Net income was $22.21 million, up 31.4%, and basic and diluted earnings per share were $0.90 compared with $0.69 per share in the same period in 2025.

Revenue growth was supported primarily by higher fuel sales and sales from new stores. Comparable store sales increased 1.3%, but comparable store sales excluding fuel decreased 1.2%, indicating that fuel was an important contributor to the reported top-line increase. The Company identified lower sales in pharmacy, dairy and produce as offsets. Pharmacy pricing headwinds related to Inflation Reduction Act Medicare maximum fair price provisions negatively affected third-quarter pharmacy sales by approximately $14.56 million and reduced total revenue growth by approximately 1.2 percentage points.

Profitability improved more rapidly than revenue. Gross profit margin increased to 25.5% from 24.8%, which management attributed to improved store inventory shrink performance and lower costs within the internal supply chain. Operating, general and administrative expenses were $296,109, compared with $286,313 in the prior-year quarter, while the improvement in gross profit supported the increase in income from operations. Lower investment income and a higher effective income tax rate moderated the earnings benefit below operating income.

For the 39-week year-to-date period, total revenue was $3.81 billion, up 4.1%, gross profit increased 7.8% to $983.26 million, and gross profit margin increased to 25.9% from 25.0%. Income from operations increased 28.6% to $93.31 million, while net income increased 18.1% to $72.92 million and earnings per share totaled $2.95. Year-to-date comparable store sales increased 1.9%, but comparable store sales excluding fuel decreased 0.1%.

Capital returns were limited in the release to the declared quarterly cash dividend of $0.34 per share. The filing provided no forward financial outlook, cash-flow figures, cash balance, debt balance, or share-repurchase disclosure. Near-term attention centers on fuel-supported sales, pharmacy pricing pressure, non-fuel comparable-store sales, dairy egg pricing, and produce demand following the Cyclospora outbreak.

Management, verbatim

In the third quarter we delivered higher total revenue and improved earnings while customers remained cautious with their spending and continued to seek affordability and value.

Jonathan H. Weis, Chairman, President and CEO

Improved store inventory shrink performance and lower costs within our internal supply chain helped drive a higher gross profit margin.

Jonathan H. Weis, Chairman, President and CEO

Not in the filing

stated, not guessed
  • Forward revenue guidance
  • Forward gross-margin guidance
  • Forward operating-expense guidance
  • Forward tax-rate guidance
  • Prior guidance for comparison
  • Cash balance
  • Debt balance
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Share repurchases
  • Segment revenue disclosures
  • Segment profit disclosures
  • Effective income tax rate
  • Non-GAAP earnings measures other than two-year stacked comparable store sales

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Weis Markets, a mid‑Atlantic grocery chain, filed its Form 8‑K Q3 2026 results.

Company-level read

Ticker impact

$WMKBullishHigh confidence
Context

Weis Markets reported Q3 2026 earnings with revenue up 3% and EPS $0.90, beating prior year.

Expected impact

potential modest upside as market prices in earnings beat and dividend

Evidence & confidence

Revenue growth, higher gross margin, and a new $0.34 dividend suggest improved fundamentals.

Market effects

Positive earnings may lift regional grocery retail sector sentiment.

Mid-Atlantic retail stocks could see modest gains.

Limited to U.S. grocery sector.

Counterpoint

Higher fuel sales may be temporary; inflation pressures could weigh on future quarters.

Key entities

  • Jonathan H. Weis

    Chairman, President and CEO of Weis Markets.

Every WMK earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$WMKHighAI 8/10

WEIS MARKETS REPORTS THIRD QUARTER 2026 RESULTS

Weis Markets (WMK) reported Q3 2026 revenue of $1.28B, up 3.0% YoY, with comparable store sales rising 1.3%. Gross profit increased 5.8% to $324.61M, and net income rose 31.4% to $22.21M. Year-to-date revenue grew 4.1% to $3.81B, with net income up 18.1% to $72.92M. The company cited higher fuel sales and new stores as growth drivers, while pharmacy pricing changes and lower produce demand moderated performance. The board declared a $0.34 per share quarterly dividend.

$WMKMedAI 8/10

WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS

Weis Markets (NYSE: WMK) reported Q2 2026 total revenue of $1.28 billion, up 4.6% from $1.22 billion in Q2 2025. Comparable store sales rose 2.3% year over year. Net income fell to $22.86 million, down 9.6%, and EPS was $0.92. Pharmacy revenue faced Medicare pricing headwinds. A $0.34 quarterly dividend was declared.

$WMKMed

WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS

WEIS MARKETS INC (WMK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ NEWS RELEASE ​ FOR IMMEDIATE RELEASE Contact: Dennis Curtin Weis Markets, Inc. 570-847-3636 dennis.curtin@weismarkets.com ​ ​ WEIS MARKETS REPORTS SECOND QUARTER 2026 RESULTS Second Quarter 2026 total revenue increased 4.6% and comparable store sales increased 2.

$SAROMed

StandardAero (SARO) Q3 2026 Earnings Call Transcript

StandardAero reported Q3 2026 earnings with 30% year-over-year adjusted EPS growth, 15% adjusted EBITDA growth, and a 130 basis points adjusted EBITDA margin expansion to 14.4%. Revenue grew across commercial aerospace, business aviation, and military & helicopter sectors. The company highlighted strong demand visibility and strategic investments driving long-term growth.

$PCTYHighAI 8/10

Paylocity (PCTY) Q1 2027 Earnings Call Transcript

Paylocity (PCTY) reported Q1 2027 recurring revenue of $424.5M, up 12% YoY, and total revenue of $451.7M, up 11%. The company launched Recruiting Optimizer, an AI-driven tool that improved recruiting productivity by 35% and filled roles 25% faster. Paylocity raised fiscal 2027 guidance and repurchased 1.1M shares at $139 each. The company highlighted strong client adoption of its AI platform and received industry recognitions.